GLI1 and cancer: Detection of pPD-1+ T cells in biopsies of cancer patients might serve as a biomarker for identification of patients with T cells subjected to PD-1-mediated immunosuppression, who would be suitable candidates for PD-1-checkpoint immunotherapy.